Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa study of PM1016 in advanced solid tumors
ChiCTR2100045182Phase 2Recruiting
- Sponsor
- Shanghai East Hospital
- Start
- May 2021
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of PM1016 in Nonhematologic neoplasms (2 arms), sponsored by Shanghai East Hospital. Primary endpoints: Treatment-emergent adverse events, Clinically significant safety assessments and 1 more. Started May 2021; status: recruiting.
02
Drugs
PM1016
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2100045182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045182.